{
    "organizations": [],
    "uuid": "ee4383226a6d69b612ca4cc2c7acc10b15b456e9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-allena-pharmaceuticals-reports-q1/brief-allena-pharmaceuticals-reports-q1-loss-per-share-0-38-idUSASC0A0G4",
    "ord_in_thread": 0,
    "title": "BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Allena Pharmaceuticals Inc:\n* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q1 LOSS PER SHARE $0.38 * Q1 EARNINGS PER SHARE VIEW $-0.43 â€” THOMSON REUTERS I/B/E/S\n* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS WERE $86.4 MILLION, VERSUS $94.5 MILLION AS OF DECEMBER 31, 2017\n* CONTINUES TO EXPECT EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2020 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T20:15:00.000+03:00",
    "crawled": "2018-05-09T12:54:58.052+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "allena",
        "pharmaceutical",
        "inc",
        "allena",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "march",
        "cash",
        "cash",
        "equivalent",
        "million",
        "versus",
        "million",
        "december",
        "continues",
        "expect",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "sufficient",
        "fund",
        "operation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}